AVEO Oncology, a Cambridge company looking to develop a potential treatment for advanced kidney cancer, said Tuesday that it has embarked on a “strategic restructuring” that will result in a reduction in force of 45 positions, or 17 percent of its workforce, as well as the elimination of 30 open positions. The reduction is part of a cost-savings program that is expected to save the company $100 million over the next three years, with $37 million of those savings projected to come in 2013. The restructuring will enable AVEO to extend its cash runway through 2013.
Unlimited access to BostonGlobe.com for only 99 cents for the first 4 weeks.Sign up
Are you a home delivery subscriber?
Get FREE access as part of your print subscriptionStart Here
Contact us for help